Cytek Biosciences, Inc. CTKB
We are a leading cell analysis solutions company advancing the next generation of research and clinical tools with our novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells ("Full Spectrum Profiling" or "FSP" technology). Our goal is to become the premier cell analysis company through continued innovation that facilitates scientific advances in biomedical research and clinical applications.
Biological systems are highly complex, and scientists are challenged by the multitude of questions that remain unanswered. Analysis at the single-cell level is essential to understand these complex systems. Identifying the correct cell in the context of a given biological question can have profound implications for drug development and health care decisions. It is essential to correlate information derived from multiple cell analysis approaches and to translate what is known at the gene level to the actual cell function. As a result, there is growing demand for deep content through high dimensional cell analysis and for solutions that can provide a complete picture of cellular biological processes and interactions. To achieve this, scientists need to phenotype and isolate rare events or unique populations down to the single-cell level through highly resolvable multi-dimensional cell analysis. While flow cytometry is a widely used tool for single cell analysis, conventional flow cytometry, mass cytometry and early approaches to spectral flow cytometry technologies have historically been challenged due to limited dimensionality, sub-optimal resolution, low throughput, high cost for performance and/or significant technical expertise required to operate systems.
Valuation FY2025 figures against the last close
Where the revenue comes from as reported in the latest 10-K
Revenue by geography
- United States
- Emea
- Apac
- Other
| Region | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| United States | $95.2M | $92.6M | $102.1M |
| Emea | $55.9M | $62.3M | $53.2M |
| Apac | $41.1M | $35.8M | $31.6M |
| Other | $9.3M | $9.7M | $6.2M |
As the company reported it, from the “Segment Information and Geographic Data - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $201.5M | $200.5M | $193.0M | $164.0M | $128.0M | $92.8M | — |
| Cost of revenue | $97.0M | $89.3M | $83.6M | $63.1M | $48.8M | $41.1M | — |
| Gross profit | $104.5M | $111.1M | $109.4M | $101.0M | $79.1M | $51.7M | — |
| R&D | $36.5M | $39.4M | $44.2M | $34.9M | $24.4M | $13.7M | — |
| SG&A | $58.9M | $43.1M | $44.0M | $34.7M | $20.8M | $9.4M | — |
| Total operating expenses | $144.8M | $131.6M | $137.3M | $102.8M | $70.0M | $38.1M | — |
| Operating income | -$40.4M | -$20.5M | -$27.8M | -$1.8M | $9.2M | $13.7M | — |
| Interest expense | $474.0K | $5.2M | $2.1M | $2.6M | $1.7M | $333.0K | — |
| Pre-tax income | -$29.8M | -$5.7M | -$15.7M | $1.3M | $5.9M | $14.4M | — |
| Income tax | $36.7M | $320.0K | $3.6M | $1.2M | $2.9M | $5.0M | — |
| Net income | -$66.5M | -$6.0M | -$12.1M | $2.5M | $3.0M | $19.4M | — |
| EPS, basic | — | — | -0.09 | 0.02 | 0.00 | 0.11 | — |
| EPS, diluted | — | — | -0.09 | 0.02 | 0.00 | 0.10 | — |
| Shares, diluted (wtd. avg.) | 127.7M | 130.6M | 135.3M | 138.6M | 81.5M | 32.6M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $90.9M | $98.7M | $167.6M | $299.5M | $364.6M | $166.1M | $30.5M |
| Receivables | $62.5M | $60.6M | $55.9M | $48.9M | $29.8M | $17.0M | — |
| Inventory | $48.4M | $43.9M | $60.9M | $48.2M | $32.2M | $23.0M | — |
| Total current assets | $392.0M | $396.4M | $392.1M | $454.0M | $431.7M | $208.6M | — |
| Property, plant and equipment | $18.0M | $18.0M | $18.4M | $13.7M | $5.9M | $2.1M | — |
| Goodwill | $16.7M | $16.7M | $16.2M | $10.1M | $10.1M | $476.0K | — |
| Other intangibles | $16.8M | $20.1M | $23.1M | $4.3M | $4.7M | $274.0K | — |
| Total assets | $461.5M | $499.5M | $494.5M | $519.5M | $463.3M | $220.0M | — |
| Accounts payable | $23.4M | $21.4M | $20.0M | $21.1M | $15.3M | $9.0M | — |
| Total current liabilities | $77.8M | $67.7M | $56.2M | $49.0M | $33.2M | $26.5M | — |
| Total liabilities | $119.8M | $103.8M | $101.4M | $93.9M | $57.9M | $41.7M | — |
| Retained earnings | -$101.7M | -$35.2M | -$29.2M | -$17.0M | -$19.6M | -$22.6M | — |
| Total equity | $341.7M | $395.7M | $393.1M | $425.5M | $405.4M | -$16.0M | $41.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.7M | $25.4M | $5.3M | -$12.2M | $4.6M | $15.2M | — |
| Depreciation and amortisation | $7.6M | $7.2M | $6.0M | $2.5M | $1.2M | $603.0K | — |
| Stock-based compensation | $24.6M | $26.8M | $22.0M | $16.6M | $6.6M | $611.0K | — |
| Capital expenditure | $4.1M | $3.5M | $4.6M | $9.7M | $4.4M | $1.5M | — |
| Investing cash flow | $10.1M | -$83.0M | -$93.9M | -$55.9M | -$21.0M | -$1.5M | — |
| Financing cash flow | -$13.4M | -$15.8M | -$41.8M | $5.5M | $213.6M | $122.6M | — |
| Buybacks | $15.1M | $21.6M | $44.2M | $0 | $0 | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-017479.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $92.8M | $128.0M | $164.0M | $193.0M | $200.5M | $201.5M |
| Gross profit | — | $51.7M | $79.1M | $101.0M | $109.4M | $111.1M | $104.5M |
| Net income | — | $19.4M | $3.0M | $2.5M | -$12.1M | -$6.0M | -$66.5M |
Recent filings and events
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Officer or director change Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Officer or director change Item 5.02
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Results announced Item 2.02
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3826
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| A | AGILENT TECHNOLOGIES, INC. | $48.79B | 37.9x | 6.7% |
| WAT | WATERS CORP /DE/ | $44.57B | 42.2x | 7.0% |
| ILMN | ILLUMINA, INC. | $40.68B | 49.4x | -0.7% |
| MTD | METTLER TOLEDO INTERNATIONAL INC/ | $33.47B | 39.7x | 4.0% |
| RVTY | REVVITY, INC. | $17.72B | 76.7x | 3.7% |
| AVTR | Avantor, Inc. | $11.80B | — | -3.4% |
| BIO | BIO-RAD LABORATORIES, INC. | $9.89B | 13.3x | 0.7% |
| TXG | 10x Genomics, Inc. | $9.30B | — | 5.2% |